Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients

Summary

The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and mortality in patients with COVID 19.

Timeline

Start

2022-02

Primary completion

2022-08

Completion

2022-08

Drugs

Indications